Protara Therapeutics, Inc. (TARA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TARA Stock Price Chart Interactive Chart >
TARA Price/Volume Stats
| Current price | $3.27 | 52-week high | $5.80 |
| Prev. close | $3.14 | 52-week low | $2.38 |
| Day low | $3.18 | Volume | 3,414 |
| Day high | $3.27 | Avg. volume | 11,356 |
| 50-day MA | $3.15 | Dividend yield | N/A |
| 200-day MA | $3.30 | Market Cap | 36.84M |
Protara Therapeutics, Inc. (TARA) Company Bio
Protara Therapeutics, Inc. operates as a biotech company. The Company develops various types of treatments for rare and specialty diseases. Protara Therapeutics serves customers in the State of New York.
Latest TARA News From Around the Web
Below are the latest news stories about PROTARA THERAPEUTICS INC that investors may wish to consider to help them evaluate TARA as an investment opportunity.
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic OncologyNEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANCED-1 Phase 1 trial at the Annual Meeting of the Society of Urologic Oncology being held in San Diego, California from November 30, 2022 through December 2, 2022. The ADVANCED-1 study is evaluating TARA-002, an investiga |
Protara Therapeutics (TARA) Investor Presentation - Slideshow (NASDAQ:TARA)The following slide deck was published by Protara Therapeutics, Inc. |
Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview- Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Following Recent Feedback from the U.S. Food and Drug Administration, Phase 2 Study of TARA-002 in Lymphatic Malformations Expected to Initiate in 2023 - - Strong Cash, Cash Equivalents and Investments Position of $107.1M as of September 30, 2022 Now Expected to Fund Operations Into 2H2024 - NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: T |
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
The Prognosis For Protara Therapeutics (NASDAQ:TARA)We put small biopharma concern Protara Therapeutics in the spotlight today for the first time in more than 18 months. Check out our analysis of TARA stock. |
TARA Price Returns
| 1-mo | 22.01% |
| 3-mo | 10.10% |
| 6-mo | -1.80% |
| 1-year | -37.24% |
| 3-year | -89.94% |
| 5-year | -96.45% |
| YTD | 22.01% |
| 2022 | -60.30% |
| 2021 | -72.12% |
| 2020 | 47.62% |
| 2019 | -81.94% |
| 2018 | 19.47% |
Loading social stream, please wait...